Effect of arsenic trioxide on rat hepatocarcinoma and its renal cytotoxicity

World Journal of Gastroenterology

Volumn 9, Issue 5, 2003, Pages 930-935

  Wang, Shao Shan ^a   Zhang, Ti ^a   Wang, Xi Lu ^a   Hong, Li ^a   Qi, Qing Hui ^b  

^a Dagang Hospital   (China)

^b Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CISPLATIN; CYCLINE; DIETHYLNITROSAMINE; PROTEIN BAX; PROTEIN BCL 2; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE; CELL CYCLE G2 PHASE; CELL KINETICS; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; ELECTRON MICROSCOPY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE CELL; LIVER CELL CARCINOMA; LIVER NECROSIS; MALE; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; OPTIMAL DRUG DOSE; ORGAN PERFUSION; PERITONEAL CAVITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; RANDOMIZATION; RAT; RAT STRAIN; STOMACH; UPREGULATION;

EID: 0037530491     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i5.930     Document Type: Article

References (45)

1. Tang ZY. Hepatocellular carcinoma - Cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
2. Vucenik I, Tantivejkul K, Zhang ZS, Cole KE, Saied I, Shamsuddin AM. IP6 in treatment of liver cancer I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 1998; 18: 4083-4090
3. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061
4. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360
5. Kerr JFR, Winterford CM, Harmon V. Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026
6. Jiang MC, Yang-Yen HF, Lin JK, Yen JJ. Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells. Oncogene 1996; 13: 609-616
7. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994; 78: 539-542
8. Zhou H, Miyaji T, Kato A, Fujigaki YK, Hishida A. Attenuation of cisplatin-induced, acute renal failure is associated with less apoptotic cell death. J Lab Clin Med 1999; 134: 649-658
9. Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ. Expanding the use of arsenic trioxide: Leukemias and beyond. Semin Hematol 2002; 39: 22-26
10. Liao C, Zhao MJ, Zhao J, Jia D, Song H, Li ZP. Over-expression of LPTS-L in hepatocellular carcinoma cell line SMMC-7721 induces crisis. World J Gastroenterol 2002; 8: 1050-1052
11. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K, Arima T. Inhibition by arsenic trioxide of human hepatocarcinoma cell growth. Cancer Lett 2002; 183: 147-153
12. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: Inhibition of proliferation and induction of apoptosis. Life Sci 2002; 71: 275-285
13. Xu HY, Yang YL, Gao YY, Wu QL, Gao GQ. Effect of arsenic trioxide on human hepatocarcinoma cell line BEL-7402 cultured in vitro. World J Gastroenterol 2000; 6: 681-687
14. Zeng WJ, Liu GY, Xu J, Zhou XD, Zhang YE, Zhang N. Pathological characteristics, PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma. World J Gastroenterol 2002; 8: 1040-1044
15. Niu ZS, Li BK, Wang M. Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues. World J Gastroenterol 2002; 8: 822-826.
16. Chen XP, Zhao H, Zhao XP. Alternation of AFP-mRNA level detected in blood circulation during liver resection for hepatocarcinoma and its significance. World J Gastroenterol 2002; 8: 818-821
17. Qiu DK, Ma X, Peng YS, Chen XY. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol 2002; 8: 815-817
18. Jiang Y, Zhou XD, Liu YK, Wu X, Huang XW. Association of hTcf-4 gene expression and mutation with clinicopathological characteristics of hepatocellular carcinoma. World J Gastroenterol 2002; 8: 804-807
19. Yang LJ, Wang WL. Preparation of monoclonal antibody against apoptosis-associated antigens of hepatocarcinoma cells by subtractive immunization. World J Gastroenterol 2002; 8: 808-814
20. Huang J, Cai MY, Wei DP. HLA class I expression in primary hepatocellular carcinoma. World J Gastroenterol 2002; 8: 654-657
21. Huang GW, Yang LY. Metallothionein expression in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 650-653
22. Liu L, Qin S, Chen H, Wang J, Chen H, Ma J, Liu W. An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes. Zhonghua Ganzangbing Zazhi 2000; 8: 367-369
23. Yang JY, Luo HY, Lin QY, Liu ZM, Yan LN, Lin P, Zhang J, Lei S. Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R. World J Gastroenterol 2002; 8: 644-649
24. Liu LX, Jiang HC, Liu ZH, Zhou J, Zhang WH, Zhu AL, Wang XQ, Wu M. Integrin gene expression profiles of human hepatocellular carcinoma. World J Gastroenterol 2002; 8: 631-637
25. Jiang HC, Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH, Wu LF. Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol 2002; 8: 624-630
26. Su JM, Gui L, Zhou YP, Zha XL. Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance. World J Gastroenterol 2002; 8: 613-618
27. Liu H, Wang Y, Zhou Q, Gui SY, Li X. The point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non hepatocarcinoma prevalent area in China. World J Gastroenterol 2002; 8: 480-482
28. Li MS, Li PF, He SP, Du GG, Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatocarcinoma Bel7402 cell line. World J Gastroenterol 2002; 8: 469-475
29. Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY, Chen JM. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 2002; 8: 464-468
30. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, Ji Y, Huang LW, Jia HL, Sun HC, Wang L. P53 immunohistochemical scoring: An independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 2002; 8: 459-463
31. Liu LX, Jiang HC, Piao DX. Radiofrequence ablation of liver cancers. World J Gastroenterol 2002; 8: 393-399
32. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-392
33. Zhang G, Long M, Wu ZZ, Yu WQ. Mechanical properties of hepatocellular carcinoma cells. World J Gastroenterol 2002; 8: 243-246
34. Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol 2002; 8: 237-242
35. Zheng N, Ye SL, Sun RX, Zhao Y, Tang ZY. Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma. World J Gastroenterol 2002; 8: 233-236
36. Hao MW, Liang YR, Liu YF, Liu L, Wu MY, Yang HX. Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. World J Gastroenterol 2002; 8: 203-207
37. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193-199
38. Wang ZX, Hu GF, Wang HY, Wu MC. Expression of liver cancer associated gene hepatocarcinoma A3. World J Gastroenterol 2001; 7: 821-825
39. Tang ZY. Hepatocellular carcinoma - Cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
40. Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol 2001; 7: 208-215
41. Sun BH, Zhang J, Wang BJ, Zhao XP, Wang YK, Yu ZQ, Yang DL, Hao LJ. Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p21(WAF1) expression and hepatic apoptosis. World J Gastroenterol 2000; 6: 356-360
42. Yang SM, Zhou H, Chen RC, Wang YF, Chen F, Zhang CG, Zhen Y, Yan JH, Su JH. Sequencing of p53 mutation in established human hepatocellular carcinoma cell line of HHC4 and HHC15 in nude mice. World J Gastroenterol 1998; 4: 506-510
43. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K, Arima T. Inhibition by arsenic trioxide of human hepatocarcinoma cell growth. Cancer Lett 2002; 183: 147-153
44. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: Inhibition of proliferation and induction of apoptosis. Life Sci 2002; 71: 275-285
45. Guo XZ, Shao XD, Liu MP, Xu JH, Ren LN, Zhao JJ, Li HY, Wang D. Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol 2002; 8: 1059-1062